Capmatinib, a highly selective MET tyrosine kinase inhibitor (TKI), has demonstrated robust efficacy in both treatment-naïve and previously treated NSCLC patients harboring METex14 skipping mutations, with overall response rates ranging from 41% to 68% and durable responses in selected individuals [8]. Here, MET is linked to non-small cell lung carcinoma.